Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Finished Goods (2019 - 2023)

Historic Finished Goods for Dna X (SONM) over the last 5 years, with Q3 2023 value amounting to $3.7 million.

  • Dna X's Finished Goods rose 466.22% to $3.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.7 million, marking a year-over-year increase of 466.22%. This contributed to the annual value of $3.5 million for FY2022, which is 1764.91% up from last year.
  • Per Dna X's latest filing, its Finished Goods stood at $3.7 million for Q3 2023, which was up 466.22% from $4.1 million recorded in Q2 2023.
  • In the past 5 years, Dna X's Finished Goods registered a high of $13.6 million during Q4 2019, and its lowest value of $2.5 million during Q2 2022.
  • Its 5-year average for Finished Goods is $5.7 million, with a median of $4.1 million in 2023.
  • Its Finished Goods has fluctuated over the past 5 years, first crashed by 6953.3% in 2022, then surged by 6784.27% in 2023.
  • Dna X's Finished Goods (Quarter) stood at $13.6 million in 2019, then tumbled by 42.53% to $7.8 million in 2020, then plummeted by 62.11% to $3.0 million in 2021, then grew by 17.65% to $3.5 million in 2022, then rose by 7.95% to $3.7 million in 2023.
  • Its Finished Goods was $3.7 million in Q3 2023, compared to $4.1 million in Q2 2023 and $3.9 million in Q1 2023.